舒血宁对早期糖尿病肾病患者白细胞介素-18的影响

目的:探讨舒血宁对早期糖尿病肾病(DN)患者血清白细胞介素-18(IL-18)水平的影响。方法:68例早期DN患者随机分为2组各34例。对照组采用糖尿病常规西医治疗加口服厄贝沙坦(150mg,qd),治疗组在对照组基础上同时给予0.9%氯化钠注射液250mL+舒血宁注射液20mL,静脉滴注,qd。2组疗程均为3周。采用酶联免疫吸附法(ELISA)测定2组治疗前、后血清IL-18水平,同时观察尿白蛋白排泄率(UAER)、空腹血糖(FPG)、血肌酐(Scr)等指标的变化。结果:与治疗前比较,2组治疗后血清IL-18水平均下降(P<0.05),与对照组比较,治疗组下降更为明显(P<0.01)。治疗组治疗后UAER明显降低(P<0.05或P<0.01)。2组治疗前后FPG、Scr差异无统计学意义(P>0.05)。结论:舒血宁对早期DN患者外周血中炎症细胞因子IL-18有抑制作用,对肾脏有保护作用,可辅助治疗糖尿病肾病。

Effect of Shuxuening on IL-18 in Patients with Early Diabetic Nephropathy

OBJECTIVE：To investigate the effect of Shuxuening on interleukin 18 （IL-18） in patients with early diabetic nephropathy.METHODS：68 patients with early diabetic nephropathy were randomly divided into 2 groups （n=34）.Both groups were given conventional diabetes therapy and oral dose of irbesartan （150 mg,qd）.Treatment group were additionally treated with Shuxuening injection 20 mL and sodium chloride injection 250 mL （i.v.qd） for 3 weeks.The levels of IL-18 of 2 groups before and after treatment were determined by enzyme-linked immunosorbent assay,and the albumin excretion rate （UAER）,fasting plasma glucose （FPG）,serum creatinine （Scr） and other indicators were also detected.RESULTS：Compared with before treatment,the levels of IL-18 of 2 groups decreased after treatment （P0.05）.The decrease of IL-18 in treatment group was more significant than in control group （P0.01）.After treatment,the UAER of treatment group after treatment was lower than before treatment （P 0.05 or P0.01）.There was no significant difference in FPG and Scr between 2 groups （P0.05）.CONCLUSION：Shuxuening can inhibit inflammatory cytokines IL-18 in peripheral blood of patients with diabetic nephropathy and have protective effects on kidney,which may be adjuvant therapy for diabetic nephropathy.